Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| OCUL - Ocular Therapeutix | 13.86% | Add +9.6% | 6,653,138 | $9.10 | $61M | +583,138 | +$33M |
| HROW - Harrow Health | 11.87% | Add +2.6% | 3,920,600 | $13.23 | $52M | +100,600 | +$9M |
| TGTX - Tg Therapeutics | 7.94% | Add +2.9% | 2,280,000 | $15.21 | $35M | +65,000 | −$3M |
| Keros Therapeutics | 5.57% | Add +2.8% | 367,500 | $66.20 | $24M | +10,000 | +$10M |
| RYTM - Rhythm Pharmaceuticals | 5.11% | Reduce −15.6% | 515,000 | $43.33 | $22M | −95,000 | −$6M |
| Catalyst Pharmaceuticals | 3.66% | Reduce −20.1% | 1,004,355 | $15.94 | $16M | −252,845 | −$5M |
| ARVN - Arvinas | 3.12% | Add +25.1% | 330,000 | $41.28 | $14M | +66,300 | +$3M |
| IOVA - Iovance Biotherapeutics | 3.04% | Hold | 897,000 | $14.82 | $13M | — | — |
| Jasper Therapeutics | 2.93% | New | 435,573 | $29.36 | $13M | +435,573 | +$13M |
| EWTX - Edgewise Therapeutics | 2.78% | Reduce −4.9% | 665,000 | $18.24 | $12M | −34,000 | +$4M |
| FDMT - 4D Molecular Therapeutics | 2.51% | Add +11.5% | 344,123 | $31.86 | $11M | +35,623 | +$5M |
| CDXS - Codexis | 2.49% | Add +2.4% | 3,120,000 | $3.49 | $11M | +74,475 | +$2M |
| Protara Therapeutics | 2.47% | Hold | 2,692,594 | $4.01 | $11M | — | — |
| Acelyrin | 2.44% | Reduce −61.9% | 1,580,000 | $6.75 | $11M | −2,566,138 | −$20M |
| ETON - Eton Pharmaceuticals | 2.10% | Reduce −3.3% | 2,445,781 | $3.75 | $9M | −84,106 | −$2M |
| TRVI - Trevi Therapeutics | 2.09% | Add +4.3% | 2,645,000 | $3.45 | $9M | +110,000 | +$6M |
| Lyell Immunopharma | 1.71% | New | 3,355,000 | $2.23 | $7M | +3,355,000 | +$7M |
| NAMS - Newamsterdam Pharma | 1.71% | Add +18.8% | 315,388 | $23.65 | $7M | +50,000 | +$4M |
| Ventyx Biosciences | 1.62% | Add +12.7% | 1,285,000 | $5.50 | $7M | +145,000 | +$4M |
| INTC - Intellia Therapeutics | 1.61% | Add +157.6% | 255,000 | $27.51 | $7M | +156,000 | +$4M |
| CMPX - Compass Therapeutics | 1.44% | New | 3,170,000 | $1.98 | $6M | +3,170,000 | +$6M |
| XOMA - XOMA Del | 1.38% | Hold | 250,000 | $24.05 | $6M | — | — |
| LQDA - Liquidia | 1.33% | Reduce −11.2% | 395,000 | $14.75 | $6M | −50,000 | +$473K |
| PCVX - Vaxcyte | 1.33% | Reduce −5.6% | 85,000 | $68.31 | $6M | −5,000 | +$154K |
| Nyxoah S A | 0.99% | Reduce −7.2% | 320,000 | $13.49 | $4M | −24,800 | +$3M |
| Savara | 0.97% | New | 855,000 | $4.98 | $4M | +855,000 | +$4M |
| Syros Pharmaceuticals | 0.96% | Add +119.1% | 787,545 | $5.35 | $4M | +428,175 | +$1M |
| URGN - Urogen Pharma | 0.93% | Reduce −15.6% | 270,000 | $15.00 | $4M | −50,000 | −$750K |
| Revance Therapeutics | 0.88% | New | 785,000 | $4.92 | $4M | +785,000 | +$4M |
| APLT - Applied Therapeutics | 0.84% | Add +62.0% | 1,770,000 | $2.07 | $4M | +677,500 | $— |
| RLMD - Relmada Therapeutics | 0.81% | Reduce −13.5% | 759,000 | $4.65 | $4M | −118,000 | −$101K |
| PTGX - Protagonist Therapeutics | 0.75% | Hold | 112,700 | $28.93 | $3M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 0.72% | New | 200,000 | $15.76 | $3M | +200,000 | +$3M |
| Allakos | 0.70% | New | 2,435,000 | $1.26 | $3M | +2,435,000 | +$3M |
| Gossamer Bio | 0.66% | Reduce −18.2% | 2,440,109 | $1.18 | $3M | −542,091 | +$158K |
| IBIO — | 0.63% | New | 680,000 | $4.06 | $3M | +680,000 | +$3M |
| VSTM - Verastem | 0.57% | Hold | 211,400 | $11.80 | $2M | — | — |
| Aligos Therapeutics | 0.37% | Add +25.7% | 1,630,000 | $0.9800 | $2M | +333,000 | +$736K |
| CNTX - Context Therapeutics | 0.35% | Add +13.7% | 1,108,357 | $1.38 | $2M | +133,357 | +$428K |
| PGEN - Precigen | 0.31% | Reduce −6.4% | 947,500 | $1.45 | $1M | −65,000 | +$17K |
| LRMR - Larimar Therapeutics | 0.30% | Reduce −72.0% | 174,413 | $7.59 | $1M | −449,087 | −$2M |
| FULC - Fulcrum Therapeutics | 0.28% | Hold | 130,000 | $9.44 | $1M | — | — |
| Morphosys AG | 0.27% | Reduce −55.2% | 65,000 | $18.14 | $1M | −80,000 | −$256K |
| GKOS - Glaukos | 0.19% | New | 8,576 | $94.29 | $809K | +8,576 | +$809K |
| Pmv Pharmaceuticals | 0.18% | New | 471,481 | $1.70 | $802K | +471,481 | +$802K |
| Biodesix | 0.17% | Add +7.7% | 534,657 | $1.43 | $765K | +38,157 | −$3M |
| Regulus Therapeutics | 0.11% | New | 170,308 | $2.88 | $490K | +170,308 | +$490K |
| DSGN - Design Therapeutics | 0.10% | New | 113,038 | $4.03 | $456K | +113,038 | +$456K |
| REPARE THERAPEUTICS | 0.07% | New | 67,561 | $4.71 | $318K | +67,561 | +$318K |
| CRNX - Crinetics Pharmaceuticals | 0.05% | Reduce −31.7% | 210,000 | $1.00 | $210K | −97,500 | −$11M |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| IDYA - Ideaya Biosciences | 2.95% | Exit | 0 | $35.58 | $11M | −311,500 | −$11M |
| BHVN - Biohaven | 2.28% | Exit | 0 | $42.80 | $9M | −200,000 | −$9M |
| ARQT - Arcutis Biotherapeutics | 1.68% | Exit | 0 | $3.23 | $6M | −1,960,000 | −$6M |
| Marinus Pharmaceuticals | 1.63% | Exit | 0 | $10.87 | $6M | −563,500 | −$6M |
| Jasper Therapeutics | 0.84% | Exit | 0 | $0.7889 | $3M | −3,985,340 | −$3M |
| Kalvista Pharmaceuticals | 0.49% | Exit | 0 | $12.25 | $2M | −150,000 | −$2M |
| Sutro Biopharma | 0.34% | Exit | 0 | $4.29 | $1M | −301,491 | −$1M |
| Kiniksa Pharmaceuticals · CLASS A | 0.17% | Exit | 0 | $17.07 | $640K | −37,500 | −$640K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2